Comparing Anti-CGRP monoclonal antibodies to OnabotulinumtoxinA for chronic migraine

A new study looks at real-word effectiveness of Anti-CGRP monoclonal antibodies & OnabotulinumtoxinA for chronic migraine. Molly O'Brien will share the study findings in this Migraine Minute News update. Read the study: https://bit.ly/4d1mPx1 *The graphic used in this content is courtesy of Grazzi, L., Giossi, R., Montisano, D.A. et al. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain 25, 14 (2024). https://doi.org/10.1186/s10194-024-01721-6. The graphical abstract has been slightly modified.